The global anti-inflammatory therapeutics market size was exhibited at USD 102.37 billion in 2022 and it is expected to hold around USD 127.5 billion by 2030, growing at a CAGR of 4.5% from 2022 to 2030.

Both acute and chronic pain, including that brought on by sprains, menstrual pain, rheumatoid arthritis, migraines, and headaches, can be reduced with the help of anti-inflammatory medications. These methods provide faster relief when compared to traditional drugs. They can also lower prostaglandin levels, inflammation-causing agents like prostaglandins, discomfort, and edema. They are capable of reducing levels of prostaglandins and other synthetic molecules responsible for inflammation, which reduces pain and swelling.

Anti-inflammatory medications often target enzymes or mediators that prevent inflammation. These medications are frequently used in combination with other medications. Among many immunological and respiratory disorders, inflammation is the most frequent adverse effect that can be treated.

Get the Sample Copy of This Report@ https://www.precedenceresearch.com/sample/2229

Market Growth

Market expansion is predicted to be fueled by increased government efforts to treat inflammation with non-steroidal anti-inflammatory drugs in Asia-Pacific and LAMEA as well as growing public awareness of anti-inflammatory medicines. This quickens the growth of the market.
 

During the forecast period, the market for anti-inflammatory therapies is anticipated to expand significantly. The market for anti-inflammatory medicines is expected to grow due to the growing prevalence of chronic diseases such as arthritis and psoriasis and the increased attention being given to these treatments. In this regard, a number of government programs have aided in raising awareness of the diseases.

Anti-Inflammatory Therapeutics Market Report Scope

Regional Analysis

The market for anti-inflammatory drugs in North America hit USD 44.39 billion in 2021. Rising demand for anti-inflammatory biologics, support from the government for the introduction of biosimilars, and high research costs are the key drivers of market growth in North America. Increased sales of Humira, Remicade, and Enbrel as well as recommendations from the Centers for Disease Control and Prevention for the usage of non-opioid drugs would further help the market.

The market for anti-inflammatory drugs is expected to grow in Europe as a result of strong government backing for the introduction of biosimilars and enticing health reimbursement policies. The primary factors driving the anti-inflammatory therapeutic market in the Asia-Pacific region are the population boom, rising healthcare costs, and growth in chronic, lifestyle-related, respiratory, and infectious diseases. Branded generics are expanding their market share as a result of more successful treatments, aggressive marketing strategies, and promotions.

Ask Here for Customization@ https://www.precedenceresearch.com/customization/2229

Market Dynamics

Drivers: Candidates in the pipeline who could increase market demand

Employing anti-tumor necrosis factor (TNF) inhibitors, interleukins, and other medicines, these businesses are focusing on treating a range of inflammatory diseases. In December 2019, for instance, UCB S.A. announced favorable results from the phase 3 clinical study of Bimekizumab for the treatment of psoriasis. Additionally, it is projected that the development of NSAIDs and corticosteroids for the treatment of acute pain, plaque psoriasis, atopic dermatitis, and other disorders will increase the market for anti-inflammatory drugs. The rise in inflammatory diseases like psoriasis, rheumatoid arthritis, ulcerative colitis, inflammatory bowel diseases, and others is one of the main factors driving the demand for anti-inflammatory medicines.

According to the Centers for Disease Control and Prevention, 78 million Americans are expected to have arthritis by 2040, with a formal medical diagnosis. The market is expected to be driven by this during the predicted period of time. Furthermore, it is projected that the market will profit from the increased incidence of atopic dermatitis and the growing usage of corticosteroids in the treatment of COPD and asthma.

Restraints: Anti-inflammatory medication side effects

Anti-inflammatory drugs work by reducing inflammation, which reduces pain. These drugs can lessen symptoms of heat, edema, stiffness, and discomfort. The analgesic effects of these drugs reduce the direct effects of inflammation on pain-nerve activation and sensitivity as well as the indirect effects of anti-inflammatory heat, knee swelling, and joint discomfort.
 

Anti-inflammatory drug use, though, may have side effects, which have grown more significant over time. Fluid retention reduced renal blood flow, and gastrointestinal bleeding is side effects of these drugs. Additionally, ingesting them results in stomach ulcers known as peptic ulcers.

Opportunities: The introduction of novel anti-inflammatory drugs

The development of novel anti-inflammatory drugs is a significant trend that is boosting the expansion of the global market for anti-inflammatory treatments. The cytokines that are produced by immune cells. In addition to being crucial for cell proliferation and differentiation, including the regulation of the immune system, these protein molecules let cells communicate with one another.

In recent years, several JAK-inhibiting small molecules have been created, and many are currently being tested in clinical settings. For the treatment of moderately to highly active RA, the US FDA has approved the small-molecule JAK pathway inhibitor XELJANZ (tofacitinib).

Drug Class Insights

Based on medication class, the market is segmented into corticosteroids, non-steroidal anti-inflammatory drugs (NDAIDs), and anti-inflammatory biologics. The anti-inflammatory biologics market accounted for the biggest share in 2021. The primary forces driving the development of this market are the advent of biosimilars, the rising use of monoclonal antibodies, and new product releases.

AbbVie released RINVOQ in August 2019 as a Janus kinase inhibitor for the treatment of rheumatoid arthritis. The NSAIDs market is anticipated to expand as a result of the rise in inflammatory diseases, rising NSAID usage, and rising demand for over-the-counter (OTC) anti-inflammatory drugs.

Distribution Insights

Regarding distribution routes, the market is split between retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacy sector dominated the market in 2018 as a result of the rising prevalence of inflammatory disorders, the increased need for anti-inflammatory drugs, favorable health reimbursement, and the market's favorable conditions. The demand for ibuprofen, diclofenac and other over-the-counter (OTC) medications is predicted to rise, along with the availability of these medications.

The US FDA granted its approval in April 2018 to Ibuprofen OTC capsules made by Strides Pharma Inc. The market for retail pharmacies should expand as a result of these items. The internet sector is anticipated to grow as a result of rising e-commerce usage, greater patient convenience, and alluring discounts and coupons on online purchases.

Application Insights

Depending on the application, the market is segmented into autoimmune inflammatory disorders, respiratory conditions, and other diseases. These include autoimmune inflammatory diseases including rheumatoid arthritis, psoriasis, and others. According to forecasts, the autoimmune inflammatory sickness market will generate the greatest revenue in 2019.

The key factors driving the segment's growth include psoriasis, inflammatory bowel diseases, and rheumatoid arthritis's rising prevalence. The market for respiratory illnesses is expected to grow over the course of the projected period as a result of a steep increase in COPD patients and rising inhalation of corticosteroids.

Related Reports

Clinical Trial Management System Market 2022 To 2030

https://www.precedenceresearch.com/clinical-trial-management-system-market

Breast Imaging Market 2022 To 2030

https://www.precedenceresearch.com/breast-imaging-market

Bone Growth Stimulators Market 2022 To 2030

https://www.precedenceresearch.com/bone-growth-stimulators-market

Recent Development

• According to a February 2021 press release from AbbVie, the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for the treatment of moderately to very active ulcerative colitis in patients 5 years of age and older.

• According to Pfizer Inc., the FDA approved tofacitinib, the substance that makes up XELJANZ XR, in October 2020 for the once-daily treatment of adult patients with moderately to severely active arthritis.

Major Key Players

Eli Lily and Company, AstraZeneca PLC, Amgen Inc., F. Hoffman, Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, Pfizer, Inc., La Roche AG, Ferring Pharmaceuticals, Bioventus, Zimmer Biomet Holdings, Inc., Flexion Therapeutics, Inc

Market Segmentation

By Drug Class

• Anti-inflammatory Biologics
• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids

By Indication

• Arthritis
  • Rheumatoid Arthritis
  • Osteoarthritis
  • Ankylosing Spondylitis
  • Psoriatic Arthritis
  • Gout
• Respiratory diseases
  • Asthma
  • Chronic obstructive pulmonary disease (COPD)
• Multiple sclerosis
• Psoriasis
• Inflammatory bowel disease
  • Crohn's Disease
  • Ulcerative Colitis
• Other inflammatory diseases 

By Application

• Autoimmune
• Inflammatory Diseases (Rheumatoid Arthritis Psoriasis)
• Respiratory Diseases

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy

Regional Segmentation

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
• Latin America (Brazil and Rest of Latin America)
• Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

https://www.precedenceresearch.com/table-of-content/2229  

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/2229

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333